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Purpose. Transrectal Ultrasound (TRUS) image is not an accurate tool to identify the presence of Extracapsular Extension (ECE).
Multiparametric MRI has by far the best spatial resolution and yields unsurpassed anatomic images of the prostate. The purpose
of this study was to evaluate the impact of intraoperative MRI/TRUS fusion procedure in cT3a prostate cancer patients treated
with HDR real time brachytherapy.
Material and methods. Prostate gland, Dominant Intraprostatic Lesions (DILs) and ECE were delineated in the pre-brachytherapy
MRI of 10 consecutive patients by two experienced uro-radiologists. Two virtual treatment plannings were performed based
on the MRI/TRUS fusion images, one considering the ECE volume and the second excluding it. The homogeneity parameters
used for optimization aim were: prostate V100>98%, V150 of 25–33%, urethral < 115% and rectal 1 cm3 <70% of prescribed dose.
The implant parameters and dose-volume histogram (DVH) related parameters of the prostate, OARs and ECE were compared
between both plans.
Results. The median prostate volume was 23.4 cm3 (19–35), median number of needles 16 (13–17) for both plans. Median radial
distance of ECE was 3.4mm (2.0–5.4) No signiﬁcant differences were found between prostate V100, V150, V200 and OARs DVH
related parameters. Values of ECE V150 and V200 were signiﬁcantly higher in the dosimetric plan when considering the presence
of ECE (p=0.002 and p=0.004, respectively) and there was a trend toward signiﬁcance for ECE V100 (p=0.06). Only one patient in
the ECE group required an additional needle to get an optimal prostate dosimetry. To our knowledge this is the ﬁrst study reporting
the dosimetric impact of TRUS/MRI fusion in the coverage of ECE in T3a patients treated with HDR real time brachytherapy.
Conclusions. TRUS/MRI fusion provides important information for prostate brachytherapy, allowing for better coverage and higher
doses to the ECE region in patients with clinical stage T3a.
http://dx.doi.org/10.1016/j.rpor.2013.03.034
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Introduction. In the last years, accelerated partial breast irradiation (APBI) has been included in protocols of good clinical practice
and recommendations of scientiﬁc societies. This is the case of ASTRO or GEC-ESTRO, which issued these recommendations after
a thorough review of the literature, chief among them being the proper selection of patients to be treated. This includes patients
with the following characteristics: T<2 cm, free surgical margins, no extensive intraductal component, ductal carcinoma, no
lymphovascular invasion, negative nodes and age>60.
Objective. To present the procedure performed in our center for the implementation of APBI with high-dose-rate brachytherapy
(HDR).
Materials and methods. After an exhaustive review of the literature, we decided to implement APBI in our department in the time a
patient entered into the recommended clinical indications. The technique involves performing a mammary implant with ﬂexible
tubing. These are placed in the patient using a needle and ﬁxed with a few buttons and friction washers. We administered 32Gy/8
sessions/4Gy, twice daily, 6h apart. Once the implant, the patient underwent a CT, with cuts every 2mm, and rebuilt the implant
in the planning system (Brachytherapy Planning, version 10.0.39.Varian Medical Systems). All measurements were performed
by the Department of Radiophysics. We took into account: Dmax skin, Dmax lung, V90, V100, V150, V200, D90, D100, Vref, V5Gy
lung, DHI, COIN and CI (conformity index).
Results. 93.7% of the dose covers 90% of the PTV. The CI (0.96) gives a good idea of the adequate volume coverage. Lung and skin
dose is within the values obtained in the literature. Excellent tolerance.
Conclusion. Accelerated partial breast irradiation has shown to be a reasonable alternative to conventional irradiation after con-
servative surgery in selected patients. These beneﬁts are quantiﬁed in cost-effectiveness, comfort by reducing overall treatment
time and decreased likelihood of secondary effects on adjacent organs.
http://dx.doi.org/10.1016/j.rpor.2013.03.035
